<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931342</url>
  </required_header>
  <id_info>
    <org_study_id>WO42178</org_study_id>
    <secondary_id>GOG-3051</secondary_id>
    <secondary_id>ENGOT-GYN2</secondary_id>
    <nct_id>NCT04931342</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors</brief_title>
  <official_title>A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GOG Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Network of Gynaecological Oncological Trial Groups (ENGOT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of multiple biomarker-driven treatments in&#xD;
      patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary&#xD;
      peritoneal tumors. Enrollment will take place in two phases: a preliminary phase followed by&#xD;
      a potential expansion phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Confirmed ORR is defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) (demonstrated on two consecutive occasions &gt;=4 weeks apart), as determined by the investigator according to RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>DOR is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Contral Rate (DCR)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>DCR is defined as the proportion of participants with a confirmed CR or PR, or stable disease maintained for at least 16 weeks, as determined by the investigator according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>PFS after start of treatment is defined as the time from start of treatment to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>OS after start of treatment is defined as the time from start of treatment to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed ORR as Determined by IRC (Independent Review Committee)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Confirmed ORR, as determined by the IRC according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR as Determined by IRC</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>DOR, as determined by the IRC according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR as Determined by IRC</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>DCR, as determined by the IRC according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS as Determined by IRC</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>PFS, as determined by the IRC according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Percentage of participants with adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ADA-Positive and ADA-Negative to Atezolizumab</measure>
    <time_frame>At baseline and after baseline (up to approximately 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ADA-Positive and ADA-Negative to Atezolizumab</measure>
    <time_frame>At baseline and after baseline (up to approximately 5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Ipatasertib + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Ipatasertib + Paclitaxel arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Cobimetinib arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trastuzumab Emtansine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Trastuzumab Emtansine arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atezolizumab + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Atezolizumab + Bevacizumab arm will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipatasertib</intervention_name>
    <description>Ipatasertib 400 mg will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 28 days)</description>
    <arm_group_label>Ipatasertib + Paclitaxel</arm_group_label>
    <other_name>RO5532961</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Cobimetinib will be administered by mouth at a dose of 60 mg once a day on Days 1-21 of each cycle. (Cycle length=28 days)</description>
    <arm_group_label>Cobimetinib</arm_group_label>
    <other_name>RO5514041</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab Emtansine</intervention_name>
    <description>Trastuzumab Emtansine will be administered intravenously at a dose of 3.6 mg/kg on Day 1 of each cycle. (Cycle length=21 days)</description>
    <arm_group_label>Trastuzumab Emtansine</arm_group_label>
    <other_name>RO5304020</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered intravenously at a dose of 1200 mg on Day 1 of each cycle. (Cycle length=21 days)</description>
    <arm_group_label>Atezolizumab + Bevacizumab</arm_group_label>
    <other_name>RO5541267, Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab will be administered intravenously at a dose of 15 mg/kg on Day 1 of each cycle. (Cycle length=21 days)</description>
    <arm_group_label>Atezolizumab + Bevacizumab</arm_group_label>
    <other_name>RO4876646, Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel will be administered intravenously at a dose of 80 mg/m2 on Days 1, 8, and 15 of each cycle. (Cycle length=28 days)</description>
    <arm_group_label>Ipatasertib + Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persistent or recurrent EOC that meets the following criteria: Histologically&#xD;
             confirmed non-high-grade serous, non-high-grade endometrioid epithelial ovarian,&#xD;
             fallopian tube, or primary peritoneal cancer (i.e., low-grade serous ovarian&#xD;
             carcinoma, clear cell carcinoma, mucinous carcinoma, carcinosarcoma, undifferentiated&#xD;
             carcinoma, seromucinous carcinoma, malignant Brenner tumors, Grades 1 or 2&#xD;
             endometrioid carcinoma, or small cell carcinoma of the ovary-hypercalcemic type);&#xD;
             Disease that is not amenable to curative surgery&#xD;
&#xD;
          -  Measurable disease (at least one target lesion) according to RECIST v1.1&#xD;
&#xD;
          -  Previous treatment with one to four lines of therapy, at least one of which was&#xD;
             platinum-based&#xD;
&#xD;
          -  Platinum-resistant disease (disease progression within 6 months of last platinum&#xD;
             therapy)&#xD;
&#xD;
          -  Submission of a representative tumor specimen that is suitable for central molecular&#xD;
             analysis (for mandatory NGS testing to determine treatment arm assignment)&#xD;
&#xD;
          -  Submission of stained pathology slides, along with the associated pathology report&#xD;
             (for central pathology review)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  Female of childbearing potential must be willing to comply with adequate contraception&#xD;
&#xD;
          -  In addition to the general inclusion criteria above, participants must meet all of the&#xD;
             arm-specific inclusion criteria for the respective arm&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant or breastfeed during the&#xD;
             study&#xD;
&#xD;
          -  Primary platinum-refractory disease, defined as progression during or within 4 weeks&#xD;
             after the last dose of the first-line platinum treatment&#xD;
&#xD;
          -  Histologic diagnosis of high-grade serous or high-grade endometrioid ovarian,&#xD;
             fallopian tube, or primary peritoneal cancer&#xD;
&#xD;
          -  Current diagnosis of solely borderline epithelial ovarian tumor&#xD;
&#xD;
          -  Current diagnosis of non-epithelial ovarian tumors&#xD;
&#xD;
          -  Current diagnosis of synchronous primary endometrial cancer&#xD;
&#xD;
          -  Prior history of primary endometrial cancer, with the following exception: a prior&#xD;
             diagnosis of primary endometrial cancer is permitted if it meets all of the following&#xD;
             conditions: Stage IA, no lymphovascular invasion, International Federation of&#xD;
             Gynecology and Obstetrics Grade 1 or 2, not a high-grade subtype.&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures&#xD;
&#xD;
          -  Symptomatic, untreated, or actively progressing CNS metastases&#xD;
&#xD;
          -  Severe infection within 4 weeks prior to initiation of study treatment&#xD;
&#xD;
          -  Treatment with chemotherapy, radiotherapy, antibody therapy or other immunotherapy,&#xD;
             gene therapy, vaccine therapy, or investigational therapy within 28 days prior to&#xD;
             initiation of study treatment&#xD;
&#xD;
          -  Treatment with hormonal therapy within 14 days prior to initiation of study treatment&#xD;
&#xD;
          -  In addition to the general exclusion criteria above, participants must meet all of the&#xD;
             arm-specific exclusion criteria for the respective arm&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: WO42178 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology - HOPE Wilmot</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - The Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cabrini Hospital; Cabrini Foundation</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven; Gyneacologische Oncologie</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno Bohunice</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CENTRE LEON BERARD; Département d'Hématologie et d'Oncologie</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gynäkologische Onkologie</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori Napoli;Unità Operativa Oncologia Medica Uro-Ginecologica</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC Medscan</name>
      <address>
        <city>Moskva</city>
        <state>Moskovskaja Oblast</state>
        <zip>119421</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chelyabisnk regional clinical center for oncology and nuclear medicine</name>
      <address>
        <city>Chelyabinsk</city>
        <state>Sverdlovsk</state>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève; Département d'oncologie</name>
      <address>
        <city>Genève</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adana Baskent University Medical Faculty; Oncology</name>
      <address>
        <city>Adana</city>
        <zip>01220</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baskent Universitesi Ankara Hastanesi; Tıbbi Onkoloji Bölümü</name>
      <address>
        <city>Ankara</city>
        <zip>06490</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Koc University Medical Faculty; Department of Gynecology &amp; Obstetrics</name>
      <address>
        <city>Istanbul</city>
        <zip>34010</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western General Hospital; Edinburgh Cancer Center</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust - University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>November 13, 2021</last_update_submitted>
  <last_update_submitted_qc>November 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Maytansine</mesh_term>
    <mesh_term>Ado-Trastuzumab Emtansine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

